SLS

SELLAS Life Sciences Group, Inc.

1.43 USD
+0.01 (+0.70%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

SELLAS Life Sciences Group, Inc. stock is down -7.14% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 61.54% of the previous 12 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Mar 17:34 18 Oct, 2024 0.50 CALL 677 171
28 Mar 18:53 18 Oct, 2024 2.00 CALL 2000 3944
04 Apr 18:22 18 Oct, 2024 1.50 CALL 1100 9277
04 Apr 18:24 18 Oct, 2024 1.50 CALL 800 9277
04 Apr 18:56 19 Jul, 2024 2.00 CALL 2000 8260
05 Apr 13:41 18 Oct, 2024 1.50 CALL 1000 11184
05 Apr 13:52 18 Oct, 2024 1.50 CALL 1950 11184
05 Apr 19:26 18 Oct, 2024 1.50 CALL 1201 11184
07 May 14:36 18 Oct, 2024 1.50 CALL 1875 18818
15 May 19:44 18 Oct, 2024 1.50 CALL 1138 19694

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapy that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials. The company was founded in 2012 and is headquartered in New York, New York.